Clinical outcomes after switching from bio-original Etanercept to biosimilar Etanercept (SB4) in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Etanercept (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms SMaRT
- 17 Jun 2017 Results (n=92) presented at the 18th Annual Congress of the European League Against Rheumatism.
- 17 Jun 2017 New trial record